Latest Raloxifene Stories
Research and Markets (http://www.researchandmarkets.com/reports/c10315) has announced the addition of Commercial Insight: Osteoporosis and HRT - Novel Osteoporosis Drugs Counter Generic Threat While HRT Players Regroup and Move Forward to their offering The osteoporosis and HRT market was valued at $8.3 billion in 2003 and is forecast to grow to $17.9 billion by 2014, driven by a number of novel osteoporosis drug launches before 2009.
A U.S. study of raloxifene found women had more than a 50 percent reduction in breast cancer incidence beyond the first four years of treatment.
TUESDAY, Nov. 30 (HealthDayNews) -- If you're taking raloxifene (Evista) because you have osteoporosis, a new study finds a probable added benefit: The drug may also significantly reduce your risk of developing breast cancer. The study, which appears in the Dec.
Dr. Jim Mitterando Q - I am 61 years old. Should I have a bone density test for osteoporosis and take calcium pills? A - Diagnosing and treating osteoporosis (thin bones) is somewhat controversial with many opinions and not much long-term data.